vs
CSW INDUSTRIALS, INC.（CSW）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是GLAUKOS Corp的1.6倍（$233.0M vs $143.1M），CSW INDUSTRIALS, INC.净利率更高（4.4% vs -93.4%，领先97.8%），GLAUKOS Corp同比增速更快（35.7% vs 20.3%），CSW INDUSTRIALS, INC.自由现金流更多（$22.7M vs $3.9M），过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs 5.1%）
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
CSW vs GKOS — 直观对比
营收规模更大
CSW
是对方的1.6倍
$143.1M
营收增速更快
GKOS
高出15.3%
20.3%
净利率更高
CSW
高出97.8%
-93.4%
自由现金流更多
CSW
多$18.8M
$3.9M
两年增速更快
GKOS
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $233.0M | $143.1M |
| 净利润 | $10.3M | $-133.7M |
| 毛利率 | 39.7% | -1.1% |
| 营业利润率 | 7.4% | -97.7% |
| 净利率 | 4.4% | -93.4% |
| 营收同比 | 20.3% | 35.7% |
| 净利润同比 | -61.9% | -298.0% |
| 每股收益（稀释后） | $0.62 | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSWGKOS
| Q4 25 | $233.0M | $143.1M | ||
| Q3 25 | $277.0M | $133.5M | ||
| Q2 25 | $263.6M | $124.1M | ||
| Q1 25 | $230.5M | $106.7M | ||
| Q4 24 | $193.6M | $105.5M | ||
| Q3 24 | $227.9M | $96.7M | ||
| Q2 24 | $226.2M | $95.7M | ||
| Q1 24 | $210.9M | $85.6M |
净利润CSWGKOS
| Q4 25 | $10.3M | $-133.7M | ||
| Q3 25 | $40.7M | $-16.2M | ||
| Q2 25 | $40.9M | $-19.7M | ||
| Q1 25 | $35.1M | $-18.1M | ||
| Q4 24 | $26.9M | $-33.6M | ||
| Q3 24 | $36.1M | $-21.4M | ||
| Q2 24 | $38.6M | $-50.5M | ||
| Q1 24 | $31.8M | $-40.8M |
毛利率CSWGKOS
| Q4 25 | 39.7% | -1.1% | ||
| Q3 25 | 43.0% | 78.4% | ||
| Q2 25 | 43.8% | 78.3% | ||
| Q1 25 | 44.2% | 77.2% | ||
| Q4 24 | 41.4% | 72.9% | ||
| Q3 24 | 45.6% | 76.6% | ||
| Q2 24 | 47.5% | 76.4% | ||
| Q1 24 | 44.4% | 76.3% |
营业利润率CSWGKOS
| Q4 25 | 7.4% | -97.7% | ||
| Q3 25 | 20.5% | -12.3% | ||
| Q2 25 | 20.8% | -18.3% | ||
| Q1 25 | 19.5% | -19.4% | ||
| Q4 24 | 15.3% | -27.2% | ||
| Q3 24 | 22.6% | -25.5% | ||
| Q2 24 | 24.3% | -31.3% | ||
| Q1 24 | 21.0% | -45.6% |
净利率CSWGKOS
| Q4 25 | 4.4% | -93.4% | ||
| Q3 25 | 14.7% | -12.2% | ||
| Q2 25 | 15.5% | -15.8% | ||
| Q1 25 | 15.2% | -17.0% | ||
| Q4 24 | 13.9% | -31.8% | ||
| Q3 24 | 15.8% | -22.1% | ||
| Q2 24 | 17.1% | -52.8% | ||
| Q1 24 | 15.1% | -47.7% |
每股收益（稀释后）CSWGKOS
| Q4 25 | $0.62 | $-2.34 | ||
| Q3 25 | $2.41 | $-0.28 | ||
| Q2 25 | $2.43 | $-0.34 | ||
| Q1 25 | $2.05 | $-0.32 | ||
| Q4 24 | $1.60 | $-0.56 | ||
| Q3 24 | $2.26 | $-0.39 | ||
| Q2 24 | $2.47 | $-1.00 | ||
| Q1 24 | $2.03 | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.2M | $90.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $656.2M |
| 总资产 | $2.3B | $893.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSWGKOS
| Q4 25 | $40.2M | $90.8M | ||
| Q3 25 | $31.5M | $98.2M | ||
| Q2 25 | $38.0M | $100.8M | ||
| Q1 25 | $225.8M | $114.3M | ||
| Q4 24 | $213.8M | $169.6M | ||
| Q3 24 | $273.2M | $100.1M | ||
| Q2 24 | $18.9M | $68.1M | ||
| Q1 24 | $22.2M | $42.5M |
总债务CSWGKOS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $800.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $166.0M | — |
股东权益CSWGKOS
| Q4 25 | $1.1B | $656.2M | ||
| Q3 25 | $1.1B | $769.5M | ||
| Q2 25 | $1.1B | $765.1M | ||
| Q1 25 | $1.1B | $764.0M | ||
| Q4 24 | $1.0B | $766.9M | ||
| Q3 24 | $1.0B | $668.5M | ||
| Q2 24 | $650.2M | $665.2M | ||
| Q1 24 | $615.7M | $450.7M |
总资产CSWGKOS
| Q4 25 | $2.3B | $893.5M | ||
| Q3 25 | $1.5B | $999.4M | ||
| Q2 25 | $1.5B | $987.0M | ||
| Q1 25 | $1.4B | $966.2M | ||
| Q4 24 | $1.4B | $974.8M | ||
| Q3 24 | $1.4B | $926.5M | ||
| Q2 24 | $1.1B | $919.7M | ||
| Q1 24 | $1.0B | $933.3M |
负债/权益比CSWGKOS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | $22.7M | $3.9M |
| 自由现金流率自由现金流/营收 | 9.8% | 2.7% |
| 资本支出强度资本支出/营收 | 2.6% | 2.0% |
| 现金转化率经营现金流/净利润 | 2.81× | — |
| 过去12个月自由现金流最近4个季度 | $162.0M | $-22.5M |
8季度趋势，按日历期对齐
经营现金流CSWGKOS
| Q4 25 | $28.9M | $6.8M | ||
| Q3 25 | $61.8M | $-10.1M | ||
| Q2 25 | $60.6M | $7.0M | ||
| Q1 25 | $27.3M | $-18.5M | ||
| Q4 24 | $11.6M | $507.0K | ||
| Q3 24 | $66.8M | $-9.6M | ||
| Q2 24 | $62.7M | $-18.4M | ||
| Q1 24 | $22.4M | $-33.9M |
自由现金流CSWGKOS
| Q4 25 | $22.7M | $3.9M | ||
| Q3 25 | $58.7M | $-11.7M | ||
| Q2 25 | $57.7M | $5.8M | ||
| Q1 25 | $22.8M | $-20.5M | ||
| Q4 24 | $8.5M | $-1.2M | ||
| Q3 24 | $61.3M | $-11.0M | ||
| Q2 24 | $59.6M | $-20.5M | ||
| Q1 24 | $17.5M | $-34.8M |
自由现金流率CSWGKOS
| Q4 25 | 9.8% | 2.7% | ||
| Q3 25 | 21.2% | -8.8% | ||
| Q2 25 | 21.9% | 4.7% | ||
| Q1 25 | 9.9% | -19.2% | ||
| Q4 24 | 4.4% | -1.2% | ||
| Q3 24 | 26.9% | -11.4% | ||
| Q2 24 | 26.3% | -21.4% | ||
| Q1 24 | 8.3% | -40.7% |
资本支出强度CSWGKOS
| Q4 25 | 2.6% | 2.0% | ||
| Q3 25 | 1.1% | 1.2% | ||
| Q2 25 | 1.1% | 0.9% | ||
| Q1 25 | 2.0% | 1.8% | ||
| Q4 24 | 1.6% | 1.6% | ||
| Q3 24 | 2.4% | 1.5% | ||
| Q2 24 | 1.4% | 2.2% | ||
| Q1 24 | 2.3% | 1.1% |
现金转化率CSWGKOS
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 0.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
